BWX FY2019 RESULTS

Friday 23 August 2019

Dave Fenlon, Group CEO & Managing Director

Vinod Somani, CFO

DISCLAIMER

This presentation has been prepared by BWX Limited ACN 163 488 631 (BWX) The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is provided to you on the basis that you are a "sophisticated investor" (in accordance with subsection 708(8) or (10) of the Corporations Act 2001 (Cth) (Corporations Act)) or a "professional investor" (in accordance with subsection 708(11) of the Corporations Act), to whom his presentation has been prepared by BWX Limited ACN 163 488 631 (BWX). The information contained in this presentation is for information purposes only and has been a disclosure document is not required to be given under the Corporations Act.

The information contained in this presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this presentation, BWX has not considered the objectives, financial position or needs of any particular recipient. BWX strongly suggests that investors consult a financial advisor prior to making an investment decision. This presentation is strictly confidential and is intended for the exclusive benefit of the institution to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of BWX. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of BWX, its related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation.

This presentation may include "forward looking statements". Forward looking statements can generally be identified by the use of the words "anticipate", "believe", "expect", "project", "forecast", "estimate", "likely", "intend", "should", "could", "may", "target", "plan" "guidance" and other similar expressions. Indications of, and guidance on, future earning or dividends and financial position and performance are also forward looking statements. These forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BWX and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in those statements. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward looking statements and BWX assumes no obligation to update that information.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities and neither this presentation nor anything contained in it forms the basis of any contract or commitment.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities of BWX have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

AGENDA

- 1. Highlights & Business Review
- 2. Financial Review
- 3. Strategy & Outlook
- 4. Questions







FY19 HIGHLIGHTS

NET SALES

\$149.5m

US retail market momentum 19.5% up on 1H19

GROSS MARGIN 52.7%

Stabilising +120 bps in 2H19 **UNDERLYING** EBITDA¹ \$21.3m

In line with guidance Up 100% on 1H19

BALANCE SHEET STRENGTHENED

Refinancing completed Improved terms Flexibility for growth

BRANDS HEALTHY



sukin

Sukin growth outperforming the natural segment in pharmacy

(+4.4% vs -3.7%)

ANDALOU

Andalou remains #1 in Facial Skin Care with a 15.5% share,

+0.6%

MINERAL FUSION Mineral Fusion revenue +37.5%

in 2H19

Nourished Life

Nourished Life club membership

up 29% yoy



OPERATIONAL HIGHLIGHTS

USA SALES MOMENTUM

Market share growth; multi-brand selling model.

Mineral Fusion relaunch well received; launching in mass channel February 2020.

Sukin (14 SKUs) and Andalou (37 SKUs) now available in Albertson's, #2 USA grocery chain.

BRAND EXPANSION

Sukin selling in 448 new USA doors; 318 new domestic doors; strong double digit growth recorded in UK, Canada, New Zealand, Malaysia, Singapore and China.

Mineral Fusion successfully rebranded.

Andalou Naturals completed successful trial in Priceline.

Nourished Life ready to sell internationally after systems upgrade; 29% increase in members during FY19.





OPERATIONAL HIGHLIGHTS

WAREHOUSE & PLATFORM UPDATES

Capacity to process up to 3,300 eCommerce orders in a single shift.

Integration and systems upgrade provides upside for multi-brand selling model.

USA facility consolidation delivers cost and leverage benefits.

ERP DELIVERING BENEFITS

Operational in Australia; implementation underway in USA.

Improved efficiency, data and forecast accuracy.

Increased margin visibility.

INCREASED CAPABILITY

US President appointment being finalised.

Hires in governance, sales, marketing.





35.3% of Group Revenue

Gross margin of 65-67%

(changing Daigou tax impacts)






Resilient to the impact of domestic export sales


Almost no pharmacy sales cannibalisation

#1 Natural Skincare – outstripping growth of natural pharmacy (+4.4% vs -3.7%)

#2 Total Skincare brand in Pharmacy – Sukin continues to perform strongly ²

#4 Total Skincare brand in Coles¹ – compelling sales growth (+38%)






Popular products - 2 Sukin products in Top 10 Skincare at Coles¹

Margin accretive new products – Blemish Control (\$1.4m, 3.4% sales)²

Strong pipeline of new products (rollout 2020)




ANDALOU NATURALS




#1 Facial Skincare Brand – Strong performance in US Naturals (15.5%, +0.6%)

#4 Hair Care Brand – growing share in US Naturals (7.6%, +14%)

#5 Facial Skincare Brand – US conventional





Popular products – 4 Andalou products in Top 10 Facial Skin Care (US Naturals)

CannaCell collection – launched in June 2018 – represents 21% of Total Andalou sales in Facial Skin Care


Gross margin of 43-45%

Total Andalou Sales +19% in 2019 in Whole Foods
Market (#1 Natural retailer)

^{32.5%} of Group Revenue



MINERAL FUSION



AU channel expansion – early momentum from


Priceline store test signals potential upside

#1 Cosmetics Brand – dominant market share in US Naturals

#3 Natural Cosmetics Brand in US conventional market

Regaining market share – positive early signs from packaging re-launch (01-2019)





Popular products – 16 Mineral Fusion products in Top 20 Cosmetics (US Naturals)


Outperforms – MF sales -1.6% vs. -6.2% Cosmetics (US conventional market)

16.4% of Group Revenue

Gross margin of 52-54%

NOURISHED LIFE





14% of Group Revenue

Gross margin of 35-37%

Stable performance over FY19

Member Loyalty – continued expansion of Loyalty Club (+29% in FY19)

Website upgrade – direct international shipping now available

Customer audit complete – implementing plan to enhance customer experience






Leading digital platform for deep consumer insights on natural and beauty

Measured expansion – increase in daily orders in 2H19 (+4%)

Capacity to extend Life Basics range



PERFORMANCE BY GEOGRAPHY



- Multi-brand selling model supported by channel expansion
- Mineral Fusion rebrand success
- ERP roll-out conducive to smarter working capital
- Net sales of \$2.4m; China influence sales are less than 10% of group revenues
- Opportunity to unlock this market further – not materially impacted by Daigou regulatory changes


Asia Pacific & International

- Focus on key customer relationships
- Continued roll-out of Andalou
- Roll-out of Nourished Life platform and other BWX e-commerce sites
- Potential upside once Mineral Fusion roll-out underway

Net sales revenue by region

AUD million

	FY18	FY19
Australia	77.0	62.8
USA	48.0	60.2
Other	23.6	26.5
Total	148.7	149.5





PROFIT AND LOSS

AUD million	FY18	1H19	2H19	FY19	Change
Revenue	148.7	68.1	81.5	149.5	0.5%
Gross Profit	88.3	35.1	42.9	78.0	-11.7%
Gross Profit Margin	59.4%	51.5%	52.7%	52.2%	-7.2%
EBITDA – Reported	35.3	7.2	12.6	19.8	-43.9%
EBITDA - Underlying¹	40.3	7.1	14.2	21.3	-47.2%
EBITDA margin – Underlying	27.1%	10.4%	17.4%	14.2%	-12.9%
Depreciation & Amortisation	-1.9	-1.4	-1.7	-3.1	66.5%
Interest Expense	-4.4	-2.8	-1.4	-4.2	-4.5%
Tax	-9.8	-0.4	-2.5	-2.9	-70.2%
NPAT – Reported	19.2	2.6	6.9	9.5	-70.0%
NPAT - Underlying ¹	24.2	2.5	8.5	11.0	-54.5%
EPS - Reported	14.3	2.1	5.6	7.7	-46.2%
EPS - Underlying	18.7	2.1	6.8	8.9	-52.4%
Dividends per share	7.45	-	2.7	2.7	-63.8%

Net revenue:

2H19 increase of 19.5% compared to 1H19

Gross Profit:

- Gross profit margin impacted by increased proportion of net revenue from acquired businesses, which operate at lower margins
- 120 basis points margin improvement in 2H19

Operating expenses:

Increase primarily attributable to acquired businesses
 12-month contribution during FY19

Depreciation & Amortisation:

 Higher D&A due to recognition of intangibles stemming from finalisation of Nourished Life acquisition and amortisation of the ERP

Lower tax expense:

Lower tax expense impacted by Andalou Naturals deferred payment

Dividend:

 A final fully franked dividend of 2.7 cents per share determined for FY19 within dividend payout guidance of 35-50%



BALANCE SHEET

As at 30 June 2019, the Group re-financed its debt facilities via extension until July 2022, at improved margins. The Group is compliant with all banking covenants.


Lower financial liabilities due to a \$9.2m reduction in deferred consideration/payments on acquisitions, offset by movement in working capital facility.

	FY19	
Bank debt	54.8	
Deferred consideration	12.8	
Total debt	67.6	

AUD million	June 2018	Dec 2018	June 2019	Change
Assets				
Cash	19.9	5.7	12.0	-39.7%
Trade and other receivable	es 31.2	30.4	30.9	-1.0%
Inventories	27.9	34.9	28.8	3.2%
Prepayments	1.8	6.1	3.7	105.6%
Current tax asset	0	0	1.0	
Plant and equipment	3.5	3.9	4.3	22.9%
Intangible assets and good	lwill 274.3	284.5	285.2	4.0%
Deferred tax assets	3.2	6.1	4.6	43.8%
Total assets	361.8	371.7	370.5	2.4%
Liabilities				
Trade and other payables	16.2	22.9	15.5	-4.3%
Financial liabilities	72.8	69.7	67.6	-7.1%
Current tax liabilities	1.4	0.4	0	-100.0%
Employee benefits	1.4	1.2	1.6	14.3%
Total liabilities	91.8	94.2	84.7	-7.7%
Net assets	270.0	277.5	285.8	5.8%



WORKING CAPITAL



- Improved position in second half
- Successful execution of inventory reduction plan in during 2H19
- The group reduced payables by \$7.0m in 2H19, whilst maintaining healthy cash position

BWX

INVENTORIES



- Inventory reduction projects across Australia and US delivered for both raw materials and finished goods in 2H19
- Benefits from the ERP intelligence and S&OP processes introduced during the year
- Inventory holding decreased by 17% in the second half



CASH FLOW RECONCILIATION

AUD million	1H19	2H19	FY19
EBITDA (underlying)	7.1	14.2	21.3
Working Capital movements	-4.0	1.0	-3.0
Non-Recurring Costs	-2.1	-4.5	-6.6
Interest expense	-1.9	-1.5	-3.4
Гах	-2.5	-3.5	-6.0
Other	-3.9	5.3	1.4
Operating Cash Flow	-7.3	11.0	3.7
Capital Expenditure	-2.6	-2.0	-4.6

-5.1

-5.1

Significant improvement in Operating Cash-flow in 2H19 (\$11.0m) compared to 1H19 (-\$7.3m)

Non-Recurring Costs relate to \$4.9m MBO and other restructure and acquisition costs of \$1.7m



Acquisitions





MARKET OPPORTUNITY





- By 2022 the global beauty and personal care market is expected to reach the value of U\$\$616 billion, growing at 5.8% (CAGR 2017-2022)
- The skincare segment is expected to dominate with a 26.6% share (5.7% CAGR)
- Australasia is the second largest region in terms of per capita spend on beauty and personal care, accounting for a third of the industry value in 2018
- The natural and organic personal care market is outperforming the broader market with 8.6% growth (CAGR 2016-2020 in US)

Global megatrends driving growth of Natural and Organic:

- ➤ Heightened consumer consciousness, particularly among millennials
- Willingness to pay more for natural ingredients
- Pressure on retailers to supply environmentally friendly and ethically sourced products
- Discerning consumers demanding transparency around ingredients
- eCommerce channel educating consumers directly



STRATEGIC PRIORITIES

CONNECT TO CONSUMERS



Invest more in marketing – speak directly to the consumer.

Reinforce our brand values.

Invest more in NPD to serve the consumer.

Go direct to the consumer. Leverage Nourished Life blatform.

Build a meaningful direct-to-consumer model by brand.

GO GLOBAL, GO MAINSTREAM



Grow natural segment. Compete with mainstream skincare.

Build customer and influencer base in China around key brands: Sukin, Andalou and Mineral Fusion.

Launch Nourished Life into new markets. Launch Sukin in Germany.

Invest in supermarket and mass channel relationships in key geographies.

Objective to have a \$50m supermarket skincare business in Australia and a \$75m conventional and mass skincare business in the US.

INVEST IN OURSELVES



Build capability. Lift Net Promoter score to 67%+. Be an employer of choice.


GET CLEAN & GET HEALTHY



Focus on operational efficiency. Invest in scalable systems and processes to support growth. Ensure best practice governance.

OUR STATUS

differentiate products better



Prioritise markets and channels

Unlock China platform business

better

INVEST IN OURSELVES Leading product formulators highly qualified and experienced Significant capability added Invest in developing talent Align global executive team better



forecasting accuracy

process

Modify channel and pricing





- Invest in partnerships with leading natural platforms
- Transform cost-base to fund growth
- Accelerate growth of a direct-to-consumer model per brand



- Invest in global enterprise approach to marketing
- Appoint Chief Marketing & Revenue Officer
- Launch Sukin in Germany
- Invest in CBEC capability

HORIZON ONE

- Reduce SKU count by 10%
- Exit sub brands of NE and third party representation
- Improve working capital
- Phase rollout ERP project kick-off

- Target 15% of net revenue from NPDs
- Joint business plans with key retailer customers
- Launch Chinese-influenced SKUs
- Launch Nourished Life in next two markets

HORIZON TWO

- GROW, MAINTAIN & EXIT market prioritisation strategy implemented
- Implement ERP in USA business
- Manufacture 60% of group revenue
- Lift employee engagement (Net Promotor Score 67%)

HORIZON THREE



- Become THE brand for talent + employer of choice
- Champion globally recognised natural benchmark
- Improve gross margin by 1.5-2.0%



OPERATIONAL IMPROVEMENT



OUTLOOK

BWX is well positioned with **CATEGORY LEADING BRANDS** that are **INCREASING MARKET SHARE**.

The BWX brand portfolio has non-discretionary attributes and is exposed to favourable megatrends which are accelerating growth of the natural and organic category and outpacing the growth of the global personal care and beauty industry.

Through **TARGETED INVESTMENT** in brand building, process improvement, capability and innovation, BWX is confident of driving **DEEPER CONSUMER PENETRATION** and **BASKET SIZE**, to support **20-25% REVENUE GROWTH** and **25-35% EBITDA GROWTH** in FY2020.

